Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell …
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) …
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional …
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics …
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis …
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced …
Apex Labs Files for US Patent Protecting Psychedelic Drug Delivery System
Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health …
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies …
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Zealand Pharma A/S (Nasdaq: ZEAL) today announced that Boehringer Ingelheim has reported that up to …
Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics
Beyond Celiac, the leading catalyst for a cure for celiac disease, today announces the creation …
